RT Journal Article
SR Electronic
T1 OP02 Increased incidence of hypothyroidism in breast cancer survivors – a danish population-based matched cohort study
JF Journal of Epidemiology and Community Health
JO J Epidemiol Community Health
FD BMJ Publishing Group Ltd
SP A1
OP A1
DO 10.1136/jech-2019-SSMabstracts.2
VO 73
IS Suppl 1
A1 AM Falstie-Jensen
A1 B Ozturk
A1 A Kjaersgaard
A1 E Lorenzen
A1 JD Jensen
A1 KV Reinertsen
A1 OM Dekkers
A1 M Ewertz
A1 DP Cronin-Fenton
YR 2019
UL http://jech.bmj.com/content/73/Suppl_1/A1.2.abstract
AB Background Research suggests increased risk of hypothyroidism among breast cancer survivors, but whether this risk is modified by treatment modalities is unclear. We estimated the incidence of hypothyroidism in breast cancer survivors, and in strata of treatment modalities.Methods Using nationwide registries, we identified all Danish women aged ≥35 years with non-metastatic breast cancer diagnosed from 1996 through 2009. Each breast cancer survivor was matched with up to five cancer-free women (hereafter ‘controls’) on birth year and area of residence. We excluded all women with prevalent hypothyroidism or hyperthyroidism. We considered cancer-directed treatment as the receipt of chemotherapy (yes/no), with or without radiotherapy—either to the chest wall only or with addition of the lymph nodes. Hypothyroidism was defined using diagnostic codes, and/or levothyroxine prescriptions. We calculated incidence rates (IR) of hypothyroidism per 1000 person-years and associated 95% confidence intervals (CI), and estimated hazard ratios (HR) and 95%CI of hypothyroidism using Cox regression, adjusting for comorbidities.Results We included 45,514 breast cancer survivors and 209,195 matched controls with 2,631,488 person-years of follow-up. Median follow-up was 8.4 years in the breast cancer cohort, and 10.6 years in the control cohort. Median age in both cohorts was 61 years. Breast cancer survivors had more comorbidities than the matched controls. Breast cancer survivors had higher incidence of hypothyroidism than matched controls [IR=4.3 (95%CI=4.2, 4.5), and 3.8 (95%CI=3.7, 3.9), respectively], corresponding to an adjusted HR of 1.15 (95%CI=1.09, 1.21). Breast cancer survivors who received radiotherapy to the lymph nodes with or without chemotherapy had highest risk of hypothyroidism when compared with matched controls [HR=1.66 (95%CI=1.43, 1.93) and HR=1.27 (95%CI=1.10, 1.46), respectively]. This pattern was also evident when comparing breast cancer survivors who received radiotherapy to the lymph nodes with or without chemotherapy with breast cancer survivors who did not undergo radiotherapy or chemotherapy (HR=1.65 (95%CI=1.41, 1.94) and HR=1.37, 95%CI=1.18, 1.58), respectively].Conclusion Breast cancer survivors treated with radiotherapy to the lymph nodes had excess risk of hypothyroidism compared with age-matched women from the general population, and when compared with breast cancer survivors who do not undergo nodal radiotherapy. The risk of hypothyroidism was particularly high among patients treated with both nodal radiotherapy and chemotherapy. Our findings support systematic screening for hypothyroidism during follow-up among breast cancer survivors who receive nodal radiotherapy, and especially those who receive nodal radiotherapy and chemotherapy.